Publication | Closed Access

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

Bone DiseaseThree-year Denosumab TreatmentBone Health1-Year Open-label ExtensionMenopauseMedicineOsteoporosisPostmenopausal Japanese WomenWomen's HealthMenopause Hormone Therapy